home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9409c.zip
/
M9490436.TXT
< prev
next >
Wrap
Text File
|
1994-09-19
|
2KB
|
34 lines
Document 0436
DOCN M9490436
TI Crystal-structure-based design and synthesis of novel C-terminal
inhibitors of HIV protease.
DT 9411
AU Varney MD; Appelt K; Kalish V; Reddy MR; Tatlock J; Palmer CL; Romines
WH; Wu BW; Musick L; Agouron Pharmaceuticals, Inc., San Diego,
California 92121.
SO J Med Chem. 1994 Jul 22;37(15):2274-84. Unique Identifier : AIDSLINE
MED/94334881
AB The X-ray crystal-structure-based design, synthesis, computational
evaluation, and activity of a novel class of HIV protease inhibitors are
described. The initial lead compounds 2 and 3 were designed by modeling
replacement groups for the C-terminal Val-Val-OCH3 of a known
hydroxyethylene inhibitor into the active site of the reported crystal
structure of HIV protease complexed with MVT-101. The lead compound 2
was found to be a modest inhibitor with a Ki = 1.67 microM. The X-ray
crystal structure of compound 2 complexed with HIV protease was solved
and used for subsequent design. The lead compound 3 was found to be a
more potent inhibitor with Ki = 0.2 microM, and the structure of it
complexed with HIV protease was also solved and used for subsequent
design. Modification of both the C-terminus and N-terminus of indole 3
resulted in compounds with Ki = 30 nM. Using the crystal structure of
compounds 2 and 3 with HIV protease as a starting point, the
thermodynamic cycle perturbation molecular dynamics method was applied
to a select group of compounds in order to test the accuracy of this
type of computation within a series of closely related compounds.
DE Crystallography, X-Ray *Drug Design HIV Protease Inhibitors/*CHEMISTRY
Thermodynamics JOURNAL ARTICLE
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).